GSK's Relvar Approved by European Authorities

by Kathy Jones on  November 19, 2013 at 8:28 PM Drug News
RSS Email Print This Page Comment bookmark
Font : A-A+

British pharmaceutical giant GlaxoSmithKline revealed that European authorities have approved its new inhaled drug Relvar for treating patients with asthma and chronic obstructive pulmonary disease (COPD).
 GSK's Relvar Approved by European Authorities
GSK's Relvar Approved by European Authorities

The drug is supposed to be inhaled through a palm-sized device called Ellipta and is made up of a corticosteroid, to reduce inflammation, and a novel long-acting beta-agonist that will help to open the airways.

Relvar has been developed in collaboration with Theravance and has already been approved in the United States, where it has been launched under the brand name Breo, though only for treating COPD patients. The approval by European Commission will see Theravance pay $15 million to GSK while a similar payment will be made once the product is launched across the EU.

Source: Medindia

Post a Comment

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
Notify me when reply is posted
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor
Advertisement

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook

News Category

News Archive